Ecopetrol
EC
Petroleo Brasileiro SA Petrobras
PBR
Taylor Morrison Home
TMHC
KB Home
KBH
Meritage Homes
MTH
US Stock MarketDetailed Quotes
RGEN Repligen
- 144.515
- -1.025-0.70%
Trading Dec 30 13:30 ET
8.06BMarket Cap-1032.25P/E (TTM)
144.570High140.620Low95.66KVolume143.170Open145.540Pre Close13.69MTurnover0.18%Turnover Ratio229.39P/E (Static)55.77MShares211.13052wk High4.10P/B7.51BFloat Cap113.50052wk Low--Dividend TTM51.93MShs Float327.320Historical High--Div YieldTTM2.71%Amplitude0.688Historical Low143.152Avg Price1Lot Size
About Repligen Company
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
Company Profile
SymbolRGEN
Company NameRepligen
Listing DateMay 6, 1986
Founded1981
CEOMr. Olivier Loeillot
MarketNASDAQ
Employees1783
Fiscal Year Ends12-31
Address41 Seyon Street,Building 1, Suite 100
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02453
Phone1-781-250-0111
Websitehttp://www.repligen.com
Company Executives
- Name
- Position
- Salary
- Olivier Loeillot
- Director, President and Chief Executive Officer
- 5.45M
- Jason K. Garland
- Chief Financial Officer
- 2.03M
- James R. Bylund
- Chief Operating Officer
- 3.74M
- Ralf Kuriyel, PhD
- Senior Vice President, Research and Development
- 1.66M
- Christine Gebski
- Senior Vice President, Filtration and Chromatography
- 1.66M
- Tony J. Hunt
- Executive Chairman of the Board
- 7.93M
- Glenn P. Muir
- Independent Director
- 322.84K
- Dr. Rohin Mhatre, PhD
- Independent Director
- 287.84K
- Dr. Martin D. Madaus,PhD
- Independent Director
- 453.50K
- Carrie Eglinton Manner
- Independent Director
- 287.84K
- Karen A. Dawes, M.A.
- Lead Independent Director
- 431.12K
- Margaret A. Pax
- Independent Director
- --
- Nicolas M. Barthelemy
- Independent Director
- 307.84K
- Dr. Konstantin Konstantinov, PhD
- Independent Director
- 282.84K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.